Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- Revolution Medicines, Inc.
- Study ID
- NCT07252232
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma
- Pancreatic Cancer
- Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
- Resected Pancreatic Adenocarcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- daraxonrasib — DRUGoral tablets
Study Details
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
Key Dates
- Start date
- Dec 15, 2025
- Status verified
- Apr 2026
- Primary completion
- May 10, 2029
- Completion
- Jul 10, 2030
Study Design
- Enrollment
- 500 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: daraxonrasibstudy drug
- No Intervention: SOC ObservationPatients randomized to the comparator control arm will receive SOC observation.
Primary Outcome Measure
Disease-Free Survival (DFS) per Investigator [ Time Frame: Up to approximately 5 years ]
Central Contacts
- Revolution Medicines Study Director1-844-2-REVMED
Locations (13)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of California, Los Angeles | Los Angeles | California | 90404 | |
| University of California, San Francisco | San Francisco | California | 94143 | |
| Hartford Healthcare | Hartford | Connecticut | 06103 | |
| Community Health Network | Indianapolis | Indiana | 46250 | |
| University of Kansas Medical Center Research Institute, Inc. | Lawrence | Kansas | 66045 | - |
| Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins | Baltimore | Maryland | 21287 | |
| Saint Luke's Cancer Institute | Kansas City | Missouri | 64111 | |
| Columbia University Medical Center | New York | New York | 10032 | |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | |
| Taylor Cancer Research Center | Maumee | Ohio | 43537 | |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57105 | |
| University of Utah, Huntsman Cancer Institute | Salt Lake City | Utah | 94112 | - |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | - |
Find similar trials in Los Angeles, CA
By condition
By specialty
By research site
University of California, Los Angeles· Los Angeles, CAUniversity of California, San Francisco· San Francisco, CAHartford Healthcare· Hartford, CTCommunity Health Network· Indianapolis, INUniversity of Kansas Medical Center Research Institute, Inc.· Lawrence, KSSidney Kimmel Comprehensive Cancer Center, Johns Hopkins· Baltimore, MD
Related Studies
- PANCREATIC DISEASE COHORT A Registry and Biospecimen Bank to Better Understand Pancreatic DiseaseRecruiting · Columbia University · New York, New York
- Pancreatic Cancer GeneticsRecruiting · Columbia University · New York, New York
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic CancerRecruiting · Memorial Sloan Kettering Cancer Center · New York, New York